The emerging role of somatic tumor sequencing in the treatment of urothelial cancer

doi:10.1016/j.ajur.2021.06.005

Asian Journal of Urology, 2021, 8 (4): 391-399 doi: 10.1016/j.ajur.2021.06.005

Review

Current Issue | Archive | Adv Search

The emerging role of somatic tumor sequencing in the treatment of urothelial cancer

Lexiaochuan Wen^a,Cameron J. Britton^a,Rohan Garje^b,Benjamin W. Darbro^c,Vignesh T. Packiam^d,*(

)

^a Department of Urology, Mayo Clinic, Rochester, MN, USA
^b Division of Hematology, Oncology, Blood & Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, IA, USA
^c Stead Family Department of Pediatrics, University of Iowa, Iowa City, IA, USA
^d Department of Urology, University of Iowa, Iowa City, IA, USA

Abstract
Related Citation (15)

Download:

HTML

PDF (364KB)
Export: BibTeX | EndNote (RIS)

Abstract

The development of rapid genome sequencing has greatly enhanced our understanding of the molecular biology underlying many malignancies. Whole exome sequencing has highlighted the individualistic nature of malignancies on a patient-to-patient basis and begun to revolutionize therapeutic approaches. In recent years, whole genome sequencing of urothelial malignancies has identified a host of somatic mutations which contribute to growth, progression, and metastasis of urothelial carcinoma of the bladder and upper tract urothelial carcinoma. As genetic sequencing continues, additional targets will be identified, allowing development of novel therapeutic agents targeting cancer on a molecular level, with the goal of delivering highly individualized care based on the underlying mutational profile of the patient's malignancy. In this review, we aim to discuss known genetic alterations of urothelial malignancy and the implications these mutations carry in terms of prognostication and development of targeted therapeutic agents. We will focus on RNA-expression profiling and genomic DNA profiling, with a focus on comprehensive whole exome and whole genome sequencing relative to selected urothelial carcinoma-associated genes and circulating tumor DNA analysis.

Key words： Tumor sequencing Whole exome sequencing Next-generation sequencing Somatic mutations Bladder cancer Urothelial carcinoma

Received: 17 September 2020 Available online: 20 October 2021

Corresponding Authors: Vignesh T. Packiam E-mail: vignesh-packiam@uiowa.edu

	Service
	E-mail this article
	Add to citation manager
	E-mail Alert
	Articles by authors
	Lexiaochuan Wen
	Cameron J. Britton
	Rohan Garje
	Benjamin W. Darbro
	Vignesh T. Packiam

TRENDMD:

Cite this article:

Lexiaochuan Wen,Cameron J. Britton,Rohan Garje, et al. The emerging role of somatic tumor sequencing in the treatment of urothelial cancer[J]. Asian Journal of Urology, 2021, 8(4): 391-399.

URL:

http://www.ajurology.com/EN/10.1016/j.ajur.2021.06.005 OR http://www.ajurology.com/EN/Y2021/V8/I4/391

[1]	Cancer Genome Atlas Research Network. Comprehensive genomic characterization deﬁnes human glioblastoma genes and core pathways. Nature 2008; 455:1061e8.
[2]	International Cancer Genome Consortium, Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, et al. International network of cancer genome projects. Nature 2010; 464:993e8.
[3]	Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and saturation anal-ysis of cancer genes across 21 tumour types. Nature 2014; 505:495e501.
[4]	Shoag JE, Wise DR, Sharaf RN, Sternberg CN. Somatic and germline sequencing in genitourinary oncology: Genetics for the clinician. Curr Opin Urol 2019; 29:315e8.
[5]	Mohler JL, Antonarakis ES, Armstrong AJ, D’Amico AV, Davis BJ, Dorff T, et al. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2019; 17:479e505.
[6]	Gupta S, Provenzale D, Llor X, Halverson AL, Grady W, Chung DC, et al. NCCN Guidelines insights: Genetic/familial high-risk assessment: colorectal, version 2.2019. J Natl Compr Canc Netw 2019; 17:1032e41.
[7]	Nakagawa H, Fujita M. Whole genome sequencing analysis for cancer genomics and precision medicine. Canc Sci 2018; 109:513e22.
[8]	Kamps R, Brandao RD, Bosch BJ, Paulussen AD, Xanthoulea S, Blok MJ, et al. Next-generation sequencing in oncology: Ge-netic diagnosis, risk prediction and cancer classiﬁcation. Int J Mol Sci 2017;18:308. https://doi.org/10.3390/ijms18020308.
[9]	Collins FS, Morgan M, Patrinos A. The Human Genome Project: Lessons from large-scale biology. Science 2003; 300:286e90.
[10]	Medicare Cf, Services M. Decision memo for next generation sequencing (NGS) for Medicare beneﬁciaries with advanced cancer (CAG-00450N)2018. https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAIdZ290. [Accessed 1 September 2020].
[11]	Akras Z, Bungo B, Leach BH, Marquard J, Ahluwalia M, Carraway H, et al. Primer on hereditary cancer predisposition genes included within somatic next-generation sequencing panels. JCO Precision Oncol 2019; 3:1e11.
[12]	Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Boufﬁoux C, Denis L, et al. Predicting recurrence and pro-gression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49. 466-465; discussion 475-7.
[13]	Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, et al. A consensus molecular classiﬁcation of muscle-invasive bladder cancer. Eur Urol 2020; 77:420e33.
[14]	Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014; 507:315e22.
[15]	Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499:214e8.
[16]	National Cancer Institute. The cancer genome Atlas program. 2018. https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga/studied-cancers. [Accessed 1 September 2020].
[17]	Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive molecular characteriza-tion of muscle-invasive bladder cancer. Cell 2017;171:540e56. e25. https://doi.org/10.1016/j.cell.2017.09.007.
[18]	Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature 2013; 500:415e21.
[19]	Duffy MJ, Synnott NC, O’Grady S, Crown J. Targeting p53 for the treatment of cancer. Semin Canc Biol 2020. https://doi.org/10.1016/j.semcancer.2020.07.005.S1044-579X(20)30160-7.
[20]	Malats N, Bustos A, Nascimento CM, Fernandez F, Rivas M, Puente D, et al. P53 as a prognostic marker for bladder cancer: A meta-analysis and review. Lancet Oncol 2005; 6:678e86.
[21]	Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemo-therapy in muscle-invasive bladder cancer. Eur Urol 2015; 68:959e67.
[22]	Ler LD, Ghosh S, Chai X, Thike AA, Heng HL, Siew EY, et al. Loss of tumor suppressor KDM6A ampliﬁes PRC2-regulated transcriptional repression in bladder cancer and can be tar-geted through inhibition of EZH2. Sci Transl Med 2017;9: eaai8312. https://doi.org/10.1126/scitranslmed.aai8312.
[23]	Cooley LF, Glaser AP, Meeks JJ. Mutation signatures to Pan-Cancer Atlas: Investigation of the genomic landscape of muscle-invasive bladder cancer. Urol Oncol 2020;S1078-1439(20) 30041-7. https://doi.org/10.1016/j.urolonc.2020.01.019.
[24]	Liu X, Zhang W, Geng D, He J, Zhao Y, Yu L. Clinical signiﬁ-cance of ﬁbroblast growth factor receptor-3 mutations in bladder cancer: A systematic review and meta-analysis. Genet Mol Res 2014; 13:1109e20.
[25]	Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, et al. Erdaﬁtinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med 2019; 381:338e48.
[26]	Pal SK, Rosenberg JE, Hoffman-Censits JH, Berger R, Quinn DI, Galsky MD, et al. Efﬁcacy of BGJ398, a ﬁbroblast growth factor receptor 1e3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alter-ations. Canc Discov 2018; 8:812e21.
[27]	Ross JS, Wang K, Gay LM, Al-Rohil RN, Nazeer T, Sheehan CE, et al. A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carci-noma. Clin Canc Res 2014; 20:68e75.
[28]	Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, et al. Genome sequencing identiﬁes a basis for everolimus sensitivity. Science 2012;338:221 https://doi.org/10.1126/science.1226344.
[29]	Milowsky MI, Iyer G, Regazzi AM, Al-Ahmadie H, Gerst SR, Ostrovnaya I, et al. Phase II study of everolimus in metastatic urothelial cancer. BJU Int 2013; 112:462e70.
[30]	Van Allen EM, Mouw KW, Kim P, Iyer G, Wagle N, Al-Ahmadie H, et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Canc Dis-cov 2014; 4:1140e53.
[31]	Groenendijk FH, de Jong J, Fransen van de Putte EE, Michaut M, Schlicker A, Peters D, et al. ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur Urol 2016; 69:384e8.
[32]	Glaser AP, Fantini D, Shilatifard A, Schaeffer EM, Meeks JJ. The evolving genomic landscape of urothelial carcinoma. Nat Rev Urol 2017; 14:215e29.
[33]	Glaser AP, Fantini D, Wang Y, Yu Y, Rimar KJ, Podojil JR, et al. APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response. Oncotarget 2018; 9:4537e48.
[34]	Rink M, Furberg H, Zabor EC, Xylinas E, Babjuk M, Pycha A, et al. Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive bladder cancer. Eur Urol 2013; 63:724e32.
[35]	Kim J, Mouw KW, Polak P, Braunstein LZ, Kamburov A, Kwiatkowski DJ, et al. Somatic ERCC2 mutations are associ-ated with a distinct genomic signature in urothelial tumors. Nat Genet 2016; 48:600e6.
[36]	Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ, Wobker SE, et al. Intrinsic subtypes of high-grade bladder cancer re?ect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A 2014; 111:3110e5.
[37]	Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, et al. Identiﬁcation of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Canc Cell 2014; 25:152e65.
[38]	Sjodahl G, Lauss M, Lovgren K, Chebil G, Gudjonsson S, Veerla S, et al. A molecular taxonomy for urothelial carci-noma. Clin Canc Res 2012; 18:3377e86.
[39]	Sjodahl G, Eriksson P, Liedberg F, Hoglund M. Molecular clas-siﬁcation of urothelial carcinoma: Global mRNA classiﬁcation versus tumour-cell phenotype classiﬁcation. J Pathol 2017; 242:113e25.
[40]	Mo Q, Nikolos F, Chen F, Tramel Z, Lee YC, Hayashi K, et al. Prognostic power of a tumor differentiation gene signature for bladder urothelial carcinomas. J Natl Cancer Inst 2018; 110:448e59.
[41]	Rebouissou S, Bernard-Pierrot I, de Reynies A, Lepage ML, Krucker C, Chapeaublanc E, et al. EGFR as a potential ther-apeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci Transl Med 2014;6: 244ra291 https://doi.org/10.1126/scitranslmed.3008970.
[42]	Hedegaard J, Lamy P, Nordentoft I, Algaba F, Hoyer S, Ulhoi BP, et al. Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Canc Cell 2016; 30:27e42.
[43]	Pietzak EJ, Bagrodia A, Cha EK, Drill EN, Iyer G, Isharwal S, et al. Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets. Eur Urol 2017; 72:952e9.
[44]	Alfred Witjes J, Lebret T, Comperat EM, Cowan NC, De Santis M, Bruins HM, et al. Updated 2016 EAU Guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2017; 71:462e75.
[45]	Mazza P, Moran GW, Li G, Robins DJ, Matulay JT, Herr HW, et al. Conservative management following complete clinical response to neoadjuvant chemotherapy of muscle invasive bladder cancer: Contemporary outcomes of a multi-institutional cohort study. J Urol 2018; 200:1005e13.
[46]	Robins D, Matulay J, Lipsky M, Meyer A, Ghandour R, DeCastro G, et al. Outcomes following clinical complete response to neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder in patients refusing radical cystectomy. Urology 2018; 111:116e21.
[47]	Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349:859e66.
[48]	Yin M, Joshi M, Meijer RP, Glantz M, Holder S, Harvey HA, et al. Neoadjuvant chemotherapy for muscle-invasive bladder can-cer: A systematic review and two-step meta-analysis. Oncol 2016; 21:708e15.
[49]	Oun R, Moussa YE, Wheate NJ. The side effects of platinum-based chemotherapy drugs: A review for chemists. Dalton Trans 2018; 47:6645e53.
[50]	Salminen AP, Montoya Perez I, Klén R, Ettala OO, Syva¨nen KT, Elo LL, et al. Adverse events during neoadjuvant chemo-therapy for muscle invasive bladder cancer. Bladder Cancer 2019; 5:273e9.
[51]	Raj GV, Karavadia S, Schlomer B, Arriaga Y, Lotan Y, Sagalowsky A, et al. Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. Cancer 2011; 117:276e82.
[52]	Porter MP, Kerrigan MC, Donato BM, Ramsey SD. Patterns of use of systemic chemotherapy for Medicare beneﬁciaries with urothelial bladder cancer. Urol Oncol 2011; 29:252e8.
[53]	Miron B, Hoffman-Censits JH, Anari F, O’Neill J, Geynisman DM, Zibelman MR, et al. Defects in DNA repair genes confer improved long-term survival after cisplatin-based neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol Oncol 2020; 3:544e7.
[54]	Teo MY, Bambury RM, Zabor EC, Jordan E, Al-Ahmadie H, Boyd ME, et al. DNA damage response and repair gene alter-ations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma. Clin Canc Res 2017; 23:3610e8.
[55]	Liu D, Plimack ER, Hoffman-Censits J, Garraway LA, Bellmunt J, Van Allen E, et al. Clinical validation of chemo-therapy response biomarker ERCC2 in muscle-invasive uro-thelial bladder carcinoma. JAMA Oncol 2016; 2:1094e6.
[56]	Takata R, Katagiri T, Kanehira M, Tsunoda T, Shuin T, Miki T, et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression proﬁling. Clin Canc Res 2005; 11:2625e36.
[57]	Takata R, Katagiri T, Kanehira M, Shuin T, Miki T, Namiki M, et al. Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy. Canc Sci 2007; 98:113e7.
[58]	Kakehi Y, Ozdemir E, Habuchi T, Yamabe H, Hashimura T, Katsura Y, et al. Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas. Jpn J Canc Res 1998; 89:214e20.
[59]	McConkey DJ, Choi W, Shen Y, Lee IL, Porten S, Matin SF, et al. A prognostic gene expression signature in the molecular classiﬁcation of chemotherapy-naive urothelial cancer is predictive of clinical outcomes from neoadjuvant chemo-therapy: A phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with bevacizumab in urothelial cancer. Eur Urol 2016; 69:855e62.
[60]	Hahn NM, Necchi A, Loriot Y, Powles T, Plimack ER, Sonpavde G, et al. Role of checkpoint inhibition in localized bladder cancer. Eur Urol Oncol 2018; 1:190e8.
[61]	Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Luciano R, et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): An open-label, single-arm, phase II study. J Clin Oncol 2018; 36:3353e60.
[62]	Necchi A, Raggi D, Gallina A, Ross JS, Fare E, Giannatempo P, et al. Impact of molecular subtyping and immune inﬁltration on pathological response and outcome following neoadjuvant pembrolizumab in muscle-invasive bladder cancer. Eur Urol 2020; 77:701e10.
[63]	Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in pa-tients with locally advanced and metastatic urothelial carci-noma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet 2016; 387:1909e20.
[64]	Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, et al. Clinical efﬁcacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med 2019; 25:1706e14.
[65]	Sfakianos JP, Cha EK, Iyer G, Scott SN, Zabor EC, Shah RH, et al. Genomic characterization of upper tract urothelial carcinoma. Eur Urol 2015; 68:970e7.
[66]	Hassler MR, Bray F, Catto JWF, Grollman AP, Hartmann A, Margulis V, et al. Molecular characterization of upper tract urothelial carcinoma in the era of next-generation sequencing: A systematic review of the current literature. Eur Urol 2020; 78:209e20.
[67]	Moss TJ, Qi Y, Xi L, Peng B, Kim T-B, Ezzedine NE, et al. Comprehensive genomic characterization of upper tract uro-thelial carcinoma. Eur Urol 2017; 72:641e9.
[68]	Audenet F, Isharwal S, Cha EK, Donoghue MTA, Drill EN, Ostrovnaya I, et al. Clonal relatedness and mutational dif-ferences between upper tract and bladder urothelial carci-noma. Clin Canc Res 2019; 25:967e76.
[69]	Pal SK, Bajorin D, Dizman N, Hoffman-Censits J, Quinn DI, Petrylak DP, et al. Inﬁgratinib in upper tract urothelial carci-noma versus urothelial carcinoma of the bladder and its as-sociation with comprehensive genomic proﬁling and/or cell-free DNA results. Cancer 2020; 126:2597e606.
[70]	Necchi A, Pouessel D, Leibowitz-Amit R, Flechon A, Gupta S, Barthelemy P, et al. 900P-Interim results of FIGHT-201, a phase 2, open-label, multicenter study of INCB054828 in patients (PTS) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring ﬁbroblast growth factor (FGF)/FGF receptor (FGFR) genetic alteration (GA). Ann Oncol 2018;29: viii319e20. https://doi.org/10.1093/annonc/mdy283.109. 109.